Table 2.
Clinical data of the early breast cancer (EBC) patient cohort including the patients’ characteristics, survival, histopathology and staging.
| Clinical Parameters | Values |
|---|---|
| Number of patients | 133 |
| Number of tumors | 134 |
| Age | Median 61.5 (37–84) years |
| Follow-up | Median 53.25 (21.5–68.5) months |
| PFS (progression free survival) | Median 51.5 (11–67.5) months |
| Deaths due to cancer (overall deaths) | 2 (6) |
| premenopausal | 23 |
| postmenopausal | 110 |
| Histology ductal | 97 (72%) |
| Histology lobular | 10 (8%) |
| Histology mixed + others | 27 (20%) |
| Tumors in personal history | 15 (11%) |
| pT1a (tumor 0.1–0.5 cm) | 3 (2%) |
| pT1b (tumor 0.5–1.0 cm) | 21 (16%) |
| pT1c (tumor 1.0–2.0 cm) | 70 (52%) |
| pT2 (tumor 2.0–5.0 cm) | 40 (30%) |
| pT3 (tumor > 5 cm) | 0 |
| pT4 (invasion to chest, skin, inflam. BC) | 0 |
| N+ (positive lymphatic nodes) | 26 (19%) |
| N− (negative lymphatic nodes) | 108 (81%) |
| G I (histological grade 1) | 27 (20%) |
| G II (histological grade 2) | 72 (54%) |
| G III (histological grade 3) | 27 (20%) |
| No grade | 8 (6%) |
| HR+ (positive for hormonal receptors) | 119 (89%) |
| HR− (negative for hormonal receptors) | 15 (11%) |
| HER+ (HER2 positive) | 4 (3%) |
| HER− (HER2 negative) | 125 (93%) |
| No HER | 5 (4%) |
| Ki-67 0–19% of positive cells | 100 (75%) |
| Ki-67 > 20% of positive cells | 29 (21%) |
| No Ki-67 (negative) | 5 (4%) |
| Triple negative (HR/HER2 negativity) | 12 (9%) |
| Low-risk group | 65 (49%) |
| High-risk group | 68 (51%) |